Loading clinical trials...
Loading clinical trials...
A Phase 3, Multi-Center, Open Label Study of Efficacy and Safety of PEGylated rFVIII (BAX 855) in Previously Treated Patients With Severe Hemophilia A Undergoing Surgical or Other Invasive Procedures
Conditions
Interventions
PEGylated Recombinant factor VIII (rFVIII)
Locations
22
United States
University of Florida College of Medicine
Gainesville, Florida, United States
Bleeding and Clotting Disorders Institute
Peoria, Illinois, United States
University of Louisville
Louisville, Kentucky, United States
Children's Mercy Hospitals & Clinics
Kansas City, Missouri, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania, United States
Start Date
December 20, 2013
Primary Completion Date
September 23, 2016
Completion Date
September 23, 2016
Last Updated
May 24, 2021
NCT06820515
NCT07226206
NCT05987449
NCT04563520
NCT04645199
NCT06833983
Lead Sponsor
Baxalta now part of Shire
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions